Diabetes Self-Management Blog

On November 5, the US Food and Drug Administration (FDA) approved the combination oral diabetes medicine Kombiglyze XR, a joint development of Bristol-Myers Squibb and AstraZeneca, for use in people with Type 2 diabetes. Kombiglyze XR combines saxagliptin (brand name Onglyza), a DPP-4 inhibitor, and extended-release metformin (Glucophage XR and others).

DPP-4 inhibitors work to lower blood glucose by blocking the action of an enzyme known as dipeptidyl peptidase 4, or DPP-4. DPP-4 breaks down hormones called incretins, which stimulate the release of insulin, slow stomach emptying, inhibit the release of glucagon (a hormone that signals the liver to release glucose), and enhance the survival and growth of the insulin-producing beta cells. With DPP-4 inhibited, the incretins have longer to carry out these actions. Metformin works by decreasing the amount of glucose made by the liver and by improving insulin sensitivity in the liver, muscle, and fat cells.

Kombiglyze XR will be offered in doses of 5 milligrams of saxagliptin/500 milligrams of metformin, 5 milligrams of saxagliptin/1,000 milligrams of metformin, and 2.5 milligrams of saxagliptin/1,000 milligrams of metformin to be taken once daily with food. (The maximum recommended doses are 5 milligrams of saxagliptin and 2,000 milligrams of metformin, respectively.) It is approved for use as an adjunct to diet and exercise in adults with Type 2 diabetes.

This medicine should not be used to treat Type 1 diabetes or diabetic ketoacidosis (a potentially life-threatening condition marked by a chemical imbalance in the body), and it has not been studied in combination with insulin. Because of the inclusion of metformin, Kombiglyze XR carries the risk of a rare but serious metabolic complication known as lactic acidosis. Common side effects of this medicine include upper respiratory tract infection, stuffy or runny nose and sore throat, and headache.

For more information about Kombiglyze XR, see the press release on the AstraZeneca Web site.

POST A COMMENT       
  

We are currently experiencing technical difficulties with our commenting system. Thank you for your patience as we work to resolve them.


Type 2 Diabetes
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
Discovering I Had Type 2 Diabetes (10/17/14)
Low-Carb Diet Improves Quality of Life in Type 2 Diabetes (10/07/14)
Long Hours at Low-Income Jobs Linked to Increased Diabetes Risk (10/02/14)

Oral Medicines
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)
Statins May Reduce Risk of Nerve Damage, Other Diabetes Complications (09/18/14)
New Metformin Combo Drug Approved for Type 2 Diabetes (08/13/14)
FDA Approves New Oral Drug for Type 2 Diabetes (08/07/14)

Diane Fennell
A Gram of Turmeric a Day to Keep Dementia At Bay? (11/20/14)
Some Sulfonylureas May Be Safer Than Others (11/14/14)
Mediterranean Diet May Benefit Kidneys (11/06/14)
New Metformin Combination Medicine Approved for Type 2 Diabetes (10/30/14)

 

 

Disclaimer of Medical Advice: You understand that the blog posts and comments to such blog posts (whether posted by us, our agents or bloggers, or by users) do not constitute medical advice or recommendation of any kind, and you should not rely on any information contained in such posts or comments to replace consultations with your qualified health care professionals to meet your individual needs. The opinions and other information contained in the blog posts and comments do not reflect the opinions or positions of the Site Proprietor.